Claims for Patent: 10,730,883

Summary for Patent: 10,730,883

Title:	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
Abstract:	The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Inventor(s):	Ayman ALLIAN, Jayanthy Jayanth, Ben Klünder, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Patrick J. Marroum, Peter T. Mayer
Assignee:	AbbVie Inc
Application Number:	US16/787,251
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,730,883
Patent Claims:	1. An oral extended-release solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in an amount sufficient to deliver 30 mg of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide free base equivalent, wherein oral administration of a single 30 mg dose of the solid dosage form to healthy adult subjects under fasting conditions results in a mean AUCinf from about 453 ng·hours/mL to about 660 ng·hours/mL, and a mean Cmax from about 55 ng/mL to about 85 ng/m L, of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. 2. The solid dosage form of claim 1, wherein the administration results in a mean Cmax from about 55 ng/mL to about 70 ng/mL. 3. The solid dosage form of claim 1, wherein the administration results in a Tmax from about 1.0 hour to about 4.0 hours of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide. 4. The solid dosage form of claim 3, wherein the median Tmax is about 2.0 hours. 5. An oral extended-release solid dosage form comprising (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in an amount sufficient to deliver 30 mg of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide free base equivalent, wherein the solid dosage form is bioequivalent to an oral extended-release film-coated tablet consisting of: (i) in the intragranular core: 30.7 mg of Freebase Hydrate Form C, 79.9 mg of microcrystalline cellulose, and 9.5 mg of hydroxypropyl methyl cellulose; (ii) in the extragranular core: 67.2 mg of microcrystalline cellulose, 100.6 mg of mannitol, 96.0 mg of tartaric acid, 86.5 mg of hydroxypropyl methyl cellulose, 2.4 mg of colloidal silicon dioxide/silica, and 7.2 mg of magnesium stearate; and (iii) 14.4 mg of a film coat comprising polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, and iron oxide.